GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Deferred Policy Acquisition Costs

Orphazyme AS (CHIX:ORPHAC) Deferred Policy Acquisition Costs


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Orphazyme AS (CHIX:ORPHAC) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).